Patents by Inventor Birgitte Andersen

Birgitte Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230220398
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Application
    Filed: January 6, 2023
    Publication date: July 13, 2023
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
  • Publication number: 20230088815
    Abstract: The invention provides an enzyme granule comprising a mixture of a laccase and a buffer in an amount capable of maintaining an alkaline pH.
    Type: Application
    Filed: February 4, 2021
    Publication date: March 23, 2023
    Applicant: Novozymes A/S
    Inventors: Niels-Viktor Nielsen, Ole Simonsen, Birgitte Andersen
  • Patent number: 11578329
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: February 14, 2023
    Assignees: Novo Nordisk A/S, Dicerna Pharmaceuticals, Inc.
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
  • Publication number: 20220340912
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Application
    Filed: April 19, 2022
    Publication date: October 27, 2022
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
  • Patent number: 10851356
    Abstract: The present invention relates to a method for modifying one or more characteristics of a lipase, comprising the step of associating a peptide to the lipase, wherein the peptide has at least 50% sequence identity with the amino acid sequence of at least one major lipase contact zone of the propeptide of said lipase.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: December 1, 2020
    Assignee: NOVOZYMES A/S
    Inventors: Anna Verena Reiser, Vikram Kjoeller Bhatia, Kim Borch, Christian I. Joergensen, Birgitte Andersen, Lone Baunsgaard
  • Publication number: 20190153410
    Abstract: The present invention relates to a method for modifying one or more characteristics of a lipase, comprising the step of associating a peptide to the lipase, wherein the peptide has at least 50% sequence identity with the amino acid sequence of at least one major lipase contact zone of the propeptide of said lipase.
    Type: Application
    Filed: February 5, 2019
    Publication date: May 23, 2019
    Applicant: NOVOZYMES A/S
    Inventors: Anna Verena Reiser, Vikram Kjoeller Bhatia, Kim Borch, Christian I. Joergensen, Birgitte Andersen, Lone Baunsgaard
  • Patent number: 10221404
    Abstract: The present invention relates to a method for modifying one or more characteristics of a lipase, comprising the step of associating a peptide to the lipase, wherein the peptide has at least 50% sequence identity with the amino acid sequence of at least one major lipase contact zone of the propeptide of said lipase.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: March 5, 2019
    Assignee: Novozymes A/S
    Inventors: Anna Verena Reiser, Vikram Kjoeller Bhatia, Kim Borch, Christian I. Joergensen, Birgitte Andersen, Lone Baunsgaard
  • Patent number: 10124039
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: November 13, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Publication number: 20180140673
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 24, 2018
    Applicant: Novo Nordisk A/S
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Patent number: 9895417
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: February 20, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Publication number: 20170354713
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Application
    Filed: July 7, 2017
    Publication date: December 14, 2017
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Patent number: 9833495
    Abstract: Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: December 5, 2017
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
  • Patent number: 9744213
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: August 29, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Publication number: 20170182124
    Abstract: The invention relates to a derivative of a FGF21 protein having a cysteine residue at a position corresponding to position 167, 169, 170, 171, 172, 173, 174, 175 and in particular position 180 or position 181 of mature human FGF21 and derivatives thereof having a side chain attached to this cysteine. The FGF21 derivatives of the invention display high potency towards the FGF receptors. The invention also relates to pharmaceutical compositions comprising such FGF21 derivatives and pharmaceutically acceptable excipients, as well as the medical use of the FGF21 derivatives.
    Type: Application
    Filed: March 8, 2017
    Publication date: June 29, 2017
    Inventors: Birgit Wieczorek, Tina Moeller Tagmose, Kristian Sass-Oerum, Birgitte Andersen, Joergen Olsen
  • Publication number: 20170137794
    Abstract: The present invention relates to a method for modifying one or more characteristics of a lipase, comprising the step of associating a peptide to the lipase, wherein the peptide has at least 50% sequence identity with the amino acid sequence of at least one major lipase contact zone of the propeptide of said lipase.
    Type: Application
    Filed: May 26, 2015
    Publication date: May 18, 2017
    Applicant: Novozymes A/S
    Inventors: Anna Verena Reiser, Vikram Kjoeller Bhatia, Kim Borch, Christian I. Joergensen, Birgitte Andersen, Lone Baunsgaard
  • Patent number: 9480753
    Abstract: The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: November 1, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Tina Møller Tagmose, Patrick William Garibay, Bírgítte Andersen, Henning Thøgersen, Birgit Wieczorek
  • Publication number: 20160129081
    Abstract: Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described.
    Type: Application
    Filed: November 16, 2015
    Publication date: May 12, 2016
    Inventors: Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
  • Patent number: 9279010
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: March 8, 2016
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Patent number: 9217021
    Abstract: Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: December 22, 2015
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
  • Patent number: 8802621
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: August 12, 2014
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen